Dashboard › Demo Universe › Halcyon Medical Devices
Halcyon Medical Devices · HLCN
DEMO DATAUNDERWRITING ASSUMPTIONHOLDFinancial statements DEMO DATA ANALYST PROJECTION
| $M | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $1.4B | $1.5B | $1.5B | $1.6B | $1.7B | $1.8B |
| % growth | 6.8% | 5.6% | 5.3% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% | |
| Direct costs / COGS | $407.1M | $428.4M | $445.5M | $476.0M | $499.8M | $521.7M | $544.5M | $568.4M | $593.2M |
| Gross profit (NOI for real estate) | $772.9M | $831.6M | $884.5M | $924.0M | $970.2M | $1.0B | $1.1B | $1.1B | $1.2B |
| % margin | 65.5% | 66.0% | 66.5% | 66.0% | 66.0% | 66.2% | 66.4% | 66.6% | 66.8% |
| Operating expenses (cash, adjusted) | $495.6M | $529.2M | $558.6M | $588.0M | $617.4M | $648.3M | $680.7M | $714.7M | $750.5M |
| EBITDA (company-adjusted basis) | $277.3M | $302.4M | $325.8M | $336.0M | $352.8M | $373.5M | $395.4M | $418.6M | $443.1M |
| % margin | 23.5% | 24.0% | 24.5% | 24.0% | 24.0% | 24.2% | 24.4% | 24.6% | 24.8% |
| D&A | $53.1M | $56.7M | $59.8M | $63.0M | $66.1M | $69.5M | $72.9M | $76.6M | $80.4M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $224.2M | $245.7M | $266.0M | $273.0M | $286.7M | $304.1M | $322.5M | $342.0M | $362.7M |
| Interest expense | $50.2M | $53.2M | $56.1M | $59.1M | $59.1M | $57.8M | $56.5M | $56.3M | $29.5M |
| EBT | $174.0M | $192.5M | $209.9M | $213.9M | $227.6M | $246.3M | $266.0M | $285.8M | $333.2M |
| Taxes | $43.5M | $48.1M | $52.5M | $53.5M | $56.9M | $61.6M | $66.5M | $71.4M | $83.3M |
| Net income (model basis) | $130.5M | $144.4M | $157.4M | $160.4M | $170.7M | $184.7M | $199.5M | $214.3M | $249.9M |
| Capex | $47.2M | $50.4M | $53.2M | $56.0M | $58.8M | $61.7M | $64.8M | $68.1M | $71.5M |
| Working capital & other cash items | $6.7M | $9.6M | $8.4M | $8.4M | $8.4M | $8.8M | $9.3M | $9.7M | $10.2M |
| Free cash flow | $129.6M | $141.1M | $155.6M | $159.0M | $169.6M | $183.6M | $198.3M | $213.1M | $248.6M |
Historical columns are fictional demo inputs. Projections flow from the selected scenario’s assumptions (Scenarios tab): interest accrues on beginning balances by tranche; floating tranches use MAX(SOFR, floor) + spread + scenario shock; PIK accrues to principal. FCF = net income + D&A + SBC + PIK − capex − ΔNWC / other. Impairments, restructuring and other one-offs are excluded from EBITDA and net income and sit in the cash plug.
Sources & data lineage (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |